Cara Therapeutics Inc. Stock
€0.62
Your prediction
Cara Therapeutics Inc. Stock
Pros and Cons of Cara Therapeutics Inc. in the next few years
Pros
Cons
Performance of Cara Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cara Therapeutics Inc. | -6.810% | -3.221% | -19.439% | -82.777% | -4.686% | -96.962% | -95.885% |
| Ardelyx Inc. | 0.540% | -5.482% | -15.972% | 32.578% | 3.218% | -12.905% | - |
| Salarius Pharmaceuticals Inc. | 4.250% | -0.935% | -18.462% | -68.120% | -23.604% | -98.261% | -99.994% |
| Brainstorm Cell | 1.170% | -0.896% | -1.485% | -81.710% | 114.440% | -80.717% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Let's wander through the financial labyrinth of Cara Therapeutics, a Biotechnology & Medical Research company with a U.S. ticker symbol of CARA. On first glance, Cara's balance sheet raises some eyebrows. With total assets declining from $271,157,000 in 2020 to $182,237,000 in 2022, a few alarm bells start to toll. But let's hold our horses and dig a little deeper before jumping to conclusions.
One potentially encouraging sign is Cara's control on liabilities, which are rather low. This puts the firm in a good position to weather potential storms. Furthermore, it's crucial that working capital witnessed fluctuations over the years. While it dropped from $176,582,000 in 2020 to $145,452,000 in 2022, it far outpaces total liabilities, hinting at a solid liquidity posture of the firm.
But what about the income? Sadly, net income was negative across all three years. This could be a potential red flag, and it's essential to remember net income often swings with the volatile nature of the Biotechnology and Medical Research industry. Gross profit which was at $34,601,000 in 2022, despite the downward slope of revenues, could be seen as a silver lining.
Comments
